News coverage about G1 Therapeutics (NASDAQ:GTHX) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. G1 Therapeutics earned a daily sentiment score of 0.00 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.2246735780943 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

G1 Therapeutics (NASDAQ GTHX) traded up $1.86 during trading on Friday, hitting $23.22. 70,300 shares of the stock traded hands, compared to its average volume of 91,550. G1 Therapeutics has a fifty-two week low of $12.04 and a fifty-two week high of $28.67. The stock has a market cap of $585.33 and a PE ratio of -10.80.

Several equities analysts have recently commented on the stock. BidaskClub upgraded shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 3rd. BTIG Research assumed coverage on shares of G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target on the stock. Zacks Investment Research cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. G1 Therapeutics currently has an average rating of “Buy” and a consensus target price of $31.40.

In related news, insider Mark A. Velleca sold 7,500 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $20.01, for a total value of $150,075.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $19.75, for a total transaction of $3,950,000.00. The disclosure for this sale can be found here. Insiders sold 542,156 shares of company stock valued at $10,761,689 over the last quarter.

COPYRIGHT VIOLATION NOTICE: “G1 Therapeutics (GTHX) Earning Somewhat Favorable News Coverage, Study Shows” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/12/g1-therapeutics-gthx-earning-somewhat-favorable-news-coverage-study-shows.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Stock Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related stocks with our FREE daily email newsletter.